October 2014

Contents

Editorial

• September/October 2014: Volume 15 Number 9/10

Conference reports

• 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 5-9 
September 2014, Washington, DC

• Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP

• Switch from efavirenz to rilpivirine quells CNS toxicity, improves sleep

• HIV persists in lung macrophages of people on suppressive ART

• Only 10% of veterans with HCV or HCV/HIV in the US treated for HCV



• 20th International AIDS Conference, 20-25 July 2014, Melbourne

• Update on baseline STIs in UK oral PrEP study (PROUD)

• High prevalence of COPD at baseline in START study sub-study

• Risk of CVD or type-2 diabetes according to change in BMI after starting ART

• Rosuvastatin may be partially effective in moderating residual immune activation on ART

• Reasons for loss to follow up in the Malawi Option B+ programme

Antiretrovirals

• Single-pill dolutegravir/abacavir/3TC (Triumeq) approved in EU and US

• Cobicistat and elvitegravir approved in the US as single pills

• Positive opinion to approve of darunavir/cobicistat in Europe

Pregnancy

• BHIVA pregnancy guidelines: 2014 interim update

• Raltegravir pharmacokinetics in pregnancy and neonates

• Efavirenz pharmacokinetics among pregnant women with and without tuberculosis coinfection

Guidelines

• UK updates PEP guidelines (2014): raltegravir replaces PIs and no indication if positive partner has an undetectable viral load

• US HIV guidelines for management of chronic kidney disease (IDSA, 2014)

Side effects

• Kidney signal trouble worsens over 5 years in Japanese on tenofovir

Coinfections and complications

• Immunotherapy for PML: two case reports using IL-7 and experimental recombinant JCV VP1 protein therapeutic vaccination

Hepatitis coinfection

• Daclatasvir approved in EU for HCV genotypes 1-4

• CHMP gives positive opinion to approve coformulated sofosbuvir/ledipasvir

• European activists protest at meeting of European Health Ministers for access to new HCV drugs

HIV prevention and transmission

• UK PROUD study to provide PrEP earlier than expected: planned follow-up to continue to two years

• HIV reinfection has limited impact on disease progression

Cure-related research

• Case report: Stem cell transplantation from CCR5 delta-32 homozygous donor selects for X4-tropic HIV

• Stemming the flow from HIV reservoirs with neutralising antibodies

Other news

• DSMB open report strongly supports importance of START study

PDFs

• September/October 2014: Volume 15 Number 9/10 – PDF